Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
PHASE4
The purpose of this study is to determine whether the rituximab administrat...
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
NA
This clinical trial studies fludarabine phosphate, low-dose total body irra...
Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration
N/A
In this study, investigators utilize a radiopathomics integrated Artificial...
Status
Unknown
Location
Gastrointestinal Department of First Affiliated Hospital of Zhejiang University
Start Date
2024-07-01
Trial ID
NCT06396143
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
PHASE1
This multicenter, open-label, Phase I study will evaluate the safety, effic...